Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives DOI Open Access
Whi‐An Kwon, Min-Kyung Lee

Cancers, Journal Year: 2024, Volume and Issue: 16(23), P. 4078 - 4078

Published: Dec. 5, 2024

Cisplatin-based chemotherapy has long been the standard first-line (1L) treatment for metastatic urothelial carcinoma (mUC). However, up to 50% of patients with mUC may be ineligible cisplatin owing comorbidities, necessitating alternative primary options. Immune checkpoint inhibitors (ICIs) have emerged as a vital those unable receive cisplatin. Nevertheless, prognosis advanced UC remains dire and challenges persist in optimizing 1L therapy. Recent medical advancements redirected attention towards innovative drug combinations mUC. The combination enfortumab vedotin (EV) pembrolizumab shown significantly improved overall progression-free survival rates compared alone. This can used who are cisplatin-ineligible or require alternatives chemotherapy. While platinum-based continues essential many patients, approval EV treatments signifies major breakthrough cancer care. These therapies offer enhanced outcomes terms response highlight increasing relevance ICI-containing regimens frontline review provides an exhaustive overview current landscape explores new therapeutic strategies, aim facilitating clinical decision-making guiding strategies

Language: Английский

Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy DOI Open Access
Juan Ye, Herui Wang, Samik Chakraborty

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1340 - 1340

Published: Feb. 5, 2025

Metastatic cancer poses significant clinical challenges, necessitating effective immunotherapies with minimal systemic toxicity. Building on prior research demonstrating the rWTC-MBTA vaccine’s ability to inhibit tumor metastasis and growth, this study focuses its translation by optimizing vaccine composition, dosing regimens, freezing techniques. The formula components included three TLR ligands (LTA, Poly I:C, Resiquimod) an anti-CD40 antibody, which were tested in melanoma triple-negative breast (TNBC) models. formulations categorized as rWTC-MBT (Mannan-BAM LTA, Resiquimod), rWTC-MBL (LTA), rWTC-MBP I:C), rWTC-MBR (Resiquimod). In models, all exhibited efficacy that was comparable of full vaccine, while “colder” TNBC multiple or Resiquimod alone performed best. Vaccine-induced activation dendritic cell (DC) subsets, including conventional DCs (cDCs), myeloid (mDCs), plasmacytoid (pDCs), accompanied CD80+CD86+ population induction, suggesting robust innate immune stimulation. An initial three-dose schedule followed booster doses (3-1-1-1 3-3-3-3) reduced metastatic burden effectively. Gradual (DMSO-based preservation) maintained efficacy, underscoring importance intact structure. These findings highlight potential simplified formulations, optimized dosing, techniques developing practical, scalable for cancers.

Language: Английский

Citations

0
Emerging Mechanisms and Biomarkers Associated with T-Cells and B-Cells in Autoimmune Disorders DOI
Azhagu Madhavan Sivalingam

Clinical Reviews in Allergy & Immunology, Journal Year: 2025, Volume and Issue: 68(1)

Published: Feb. 11, 2025

Language: Английский

Citations

0
Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives DOI Creative Commons
X. Shi, Kai Tang, Quanbin Zhang

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 21, 2025

Antibody-drug conjugates have emerged as a promising cancer treatment, combining targeted delivery of cytotoxic agents with the specificity monoclonal antibodies. Despite their potential, ADCs face limitations such resistance and off-target effects. To enhance efficacy, are increasingly being combined other therapeutic strategies, including immune checkpoint inhibitors, chemotherapy, small-molecule anti-angiogenic agents, CAR-T cell therapies. These combination therapies aim to overcome mechanisms, improve tumor targeting, boost responses. Clinical studies shown that combinations can significantly response rates progression-free survival across various cancers. This review explores clinical key studies, challenges, future perspectives in therapy.

Language: Английский

Citations

0
Global research progress in antibody-drug conjugates for solid tumors: Bibliometrics and visualized analysis DOI Creative Commons
Wenjun Fang,

Xueqing Ma,

Ben Liu

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)

Published: Feb. 27, 2025

Recently, the use of antibody-drug conjugates (ADCs) in research and management solid tumors has increased, making them a key focus field oncology. In this study, we performed comprehensive literature review ADCs tumor treatment. We retrieved data from Web Science Core Collection (WoSCC). Following retrieval, conducted thorough bibliometric knowledge-mapping analysis collected articles. There was rapid growth number annual publications field. The United States had highest publication volumes led ADC for tumors. Additionally, Dana-Farber Cancer Institute output, G. Curigliano identified as most productive author. journal "Cancers" publishing on Furthermore, clustering terms such "breast cancer," "targeted therapy," "bladder "ovarian "expression," "drug delivery" emerged progressed. six themes by co-citation analysis, involving application four breast cancer, well design, mechanisms, strategies reducing cytotoxicity. At same time, based papers that have experienced citation burst recently, explored future development trends Overall, our inaugural provides systematic framework to guide studies Therefore, facilitating promoting further area.

Language: Английский

Citations

0
Navigating the Landscape of Resistance Mechanisms in Antibody–Drug Conjugates for Cancer Treatment DOI

Gloria Lalli,

Ilaria Sabatucci,

Mariachiara Paderno

et al.

Targeted Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: April 15, 2025

Language: Английский

Citations

0
Advancements in antibody-drug conjugates as cancer therapeutics DOI Creative Commons

Jung Yin Fong,

Zhixin Phuna,

D. Chong

et al.

Journal of the National Cancer Center, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis DOI
Guillermo Villacampa, Pablo Cresta Morgado,

L. Carità

et al.

Cancer Treatment Reviews, Journal Year: 2024, Volume and Issue: 131, P. 102847 - 102847

Published: Oct. 18, 2024

Language: Английский

Citations

1
Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis DOI Creative Commons

Grégoire Desimpel,

François Zammit,

Sarah Lejeune

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(11), P. 1547 - 1547

Published: Nov. 18, 2024

Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) that combines monomethyl auristatin E (MMAE), a potent cytotoxic agent, with monoclonal antibody targeting Nectin-4. It has emerged as promising therapy for metastatic urothelial carcinoma (mUC), either monotherapy or in combination pembrolizumab, improving significantly the overall survival of these patients. EV associated common adverse events, including skin reactions, glucose imbalance, and peripheral neuropathy, which are usually mild severity easily manageable.

Language: Английский

Citations

1
Emerging molecular therapies in the treatment of bladder cancer DOI Creative Commons

Scott D. Bell,

Anthony E. Quinn, Tom D. Spitzer

et al.

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2024, Volume and Issue: 5(5), P. 1135 - 1154

Published: Aug. 29, 2024

Bladder cancer is a leading type in men. The complexity of treatment late-stage bladder after systemic spread through the lymphatic system highlights importance modulating disease-free progression as early possible staging. With current therapies relying on previous standards, such platinum-based chemotherapeutics and immunomodulation with Bacillus Calmette-Guerin, researchers, clinicians are looking for targeted to stop at its source progression. A new era molecular that target specific features upregulated cell lines surfacing, which may be able provide patients better control disease Here, we discuss multiple emerging including immune checkpoint inhibitors programmed death protein 1 (PD-1)/programmed ligand (PD-L1) pathway, antibody-drug conjugates, modulation phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian rapamycin (mTOR) proliferation chimeric antigen receptor T-cell therapy, fibroblast growth factor targeting. Together, these modern treatments potentially promising results possibility increasing remission survival rates.

Language: Английский

Citations

0
Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives DOI Open Access
Whi‐An Kwon, Min-Kyung Lee

Cancers, Journal Year: 2024, Volume and Issue: 16(23), P. 4078 - 4078

Published: Dec. 5, 2024

Cisplatin-based chemotherapy has long been the standard first-line (1L) treatment for metastatic urothelial carcinoma (mUC). However, up to 50% of patients with mUC may be ineligible cisplatin owing comorbidities, necessitating alternative primary options. Immune checkpoint inhibitors (ICIs) have emerged as a vital those unable receive cisplatin. Nevertheless, prognosis advanced UC remains dire and challenges persist in optimizing 1L therapy. Recent medical advancements redirected attention towards innovative drug combinations mUC. The combination enfortumab vedotin (EV) pembrolizumab shown significantly improved overall progression-free survival rates compared alone. This can used who are cisplatin-ineligible or require alternatives chemotherapy. While platinum-based continues essential many patients, approval EV treatments signifies major breakthrough cancer care. These therapies offer enhanced outcomes terms response highlight increasing relevance ICI-containing regimens frontline review provides an exhaustive overview current landscape explores new therapeutic strategies, aim facilitating clinical decision-making guiding strategies

Language: Английский

Citations

0